NCT06265558 Prevention of Postoperative Complications by Negative Pressure Therapy After Complex Breast Cancer Surgery
| NCT ID | NCT06265558 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Institut du Cancer de Montpellier - Val d'Aurelle |
| Condition | Breast Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 254 participants |
| Start Date | 2025-04-15 |
| Primary Completion | 2027-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 254 participants in total. It began in 2025-04-15 with a primary completion date of 2027-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
There is little scientific data concerning the use of negative pressure therapy after immediate breast reconstruction. That strategy of treatment-reconstruction has expanded increasingly since the last years. The current literature reports only 3 studies on the use of preventive negative pressure therapy in oncologic breast surgery. Moreover, all three are retrospective, case-control studies with serious limitations. The largest published series reports a reduction in the overall complication rate from 15.9% to 8.5%, and a significant reduction in several criteria: infection, scar dehiscence and necrosis. However, the study presents significant biases, with non-comparable populations in terms of comorbidities, surgical procedure performed, inclusion periods (and therefore experience in performing oncological surgery). There was also a high probability of under-assessment or postponement of post-operative complications, which is typical of published retrospective surgical studies. The published results therefore strongly encourage further investigation of negative pressure therapy in oncological breast surgery.
Eligibility Criteria
Inclusion Criteria: 1. Female ≥ 18 years 2. Patient with unilateral invasive or in situ breast carcinoma 3. Patient with or without neoadjuvant treatment 4. Patient presenting an indication for complex breast surgery by mastectomy with immediate breast reconstruction by implant or oncoplasty by T-shaped mammoplasty. 5. Patient presenting at least one of the following risk factors for scarring disorders: * Obesity with Body Mass Index BMI ≥ 30 and/or Cup size ≥ E * Active smoking or smoking cessation for less than one month * Diabetes * History of homolateral breast radiotherapy * Long-term corticosteroid therapy 6. Patient to have signed informed consent prior to study entry 7. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures. 8. Patient affiliated with a health insurance plan. Exclusion Criteria: 1. Legal incapacity or limited legal capacity. Medical or psychological conditions preventing the patient from completing the study or signing the consent form. 2. Pregnant or breast-feeding patient as determined in medical records as part of standard patients care and follow-up 3. Patient under guardianship or safeguard of justice 4. Patient participating in an interventional study with the objective of wound healing 5. Any concurrent or planned surgical procedure on the contralateral breast
Contact & Investigator
Mathias NERON, MD
STUDY CHAIR
Institut régional du Cancer de Montpellier (ICM)
Frequently Asked Questions
Who can join the NCT06265558 clinical trial?
This trial is open to female participants only, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06265558 currently recruiting?
Yes, NCT06265558 is actively recruiting participants. Contact the research team at mathias.neron@icm.unicancer.fr for enrollment information.
Where is the NCT06265558 trial being conducted?
This trial is being conducted at Dijon, France, Nîmes, France, Bordeaux, France, Montpellier, France and 3 additional locations.
Who is sponsoring the NCT06265558 clinical trial?
NCT06265558 is sponsored by Institut du Cancer de Montpellier - Val d'Aurelle. The principal investigator is Mathias NERON, MD at Institut régional du Cancer de Montpellier (ICM). The trial plans to enroll 254 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.